Infectious Enteritis Treatment Market

Market Overview

The global infectious enteritis treatment market size was valued at USD 420 million in 2023 and is projected to reach USD 630 million by 2032, registering a CAGR of 5.2% during the forecast period (2024-2032). The market will likely develop over the forecast period because of factors like an increasing population with irritable bowel syndrome (IBS) and a rise in incidences of diarrhea caused by infectious enteritis. 

The treatment for infectious enteritis usually consists of a combination of supportive care, hydration, and targeted antibiotic therapy. Supportive care encompasses interventions such as administering fluids and electrolytes to avoid dehydration and maintain the balance of electrolytes, particularly in severe situations where the ability to consume liquids orally is hindered. Antimicrobial therapy may be provided depending on the enteritis's hypothesized or identified causative agent, which can encompass bacteria, viruses, or parasites. The treatment approaches for infectious enteritis generally focus on relieving symptoms, preventing complications, and facilitating recovery while decreasing the likelihood of negative consequences.

Factors such as an increasing population with irritable bowel syndrome (IBS) and diarrhea caused by infectious enteritis, as well as intensive research and development activities and a rise in FDA approvals of drugs for treating contagious enteritis, are driving the market. Moreover, the market's growth is anticipated to be enhanced in the projected period due to the implementation of different strategies by major market players, including introducing new products, mergers, acquisitions, and collaborations.

Highlights

• Oral generates the highest revenue share based on the route of administration.
• Antibiotics account for the largest market share by drug type.
• Hospital pharmacy contributes significantly to the market through end use.

Market Dynamics

Global Infectious Enteritis Treatment Market Drivers

Rising Population with Irritable Bowel Syndrome (IBS) and Diarrhea

Infectious enteritis, which is the inflammation of the small intestine caused by infectious agents such as bacteria, viruses, or parasites, presents substantial healthcare obstacles on a global scale. The growing global population suffering from irritable bowel syndrome (IBS) and diarrhea is anticipated to drive the expansion of the infectious enteritis treatment market. The increasing occurrence of illnesses such as IBS and diarrhea, which are frequently linked to enteritis, highlights the necessity for efficient therapies. 

Specifically, the prevalence of Irritable Bowel Syndrome (IBS) ranges from 9% to 23% among the general population, with women accounting for 80% of the identified patients. IBS impacts a population of 25 to 45 million individuals in the United States. Approximately two-thirds of individuals with irritable bowel syndrome (IBS) are female. Approximately one-third of individuals with Irritable Bowel Syndrome (IBS) are male. According to a poll conducted by IFFGD, a substantial percentage – ranging from 35% to 40% - of individuals who claim to have IBS in the community are of the male gender. The prominence of Irritable Bowel Syndrome (IBS) is higher in females, with around 60% to 65% of patients who report having IBS in the population being female.

Therefore, as the population with irritable bowel syndrome (IBS) and occurrences of diarrhea caused by infectious enteritis increase, there is a corresponding increase in the demand for treatment. This, in turn, drives the expansion of the market throughout the projection period. 

Aging Population

The increasing proportion of elderly individuals significantly contributes to the growth of the infected enteritis treatment market. This is because the aging population tends to weaken immune systems, making them more prone to infectious enteritis. Consequently, there is a need for efficient therapies to address this issue. By 2030, the proportion of persons aged 60 years or older worldwide will be 1 in 6. The proportion of the population aged 60 years and older is estimated to rise from 1 billion in 2020 to 1.4 billion. 

Additionally, the worldwide population of those aged 60 years and over is estimated to increase double, reaching a total of 2.1 billion by the year 2050. The population of those aged 80 years or older is projected to quadruple from 2020 to 2050, reaching 426 million. Population aging, which refers to the shift in the distribution of a country's population towards older age groups, initially occurred in high-income countries. For instance, in Japan, 30% of the population is already over 60 years old. 

However, this trend is now more prominent in low- and middle-income countries. By 2050, over two-thirds of the global population aged 60 and above will reside in nations with low to intermediate economic levels. In addition, older populations generally exhibit increased rates of healthcare usage, resulting in more frequent consultations with doctors and diagnostic examinations. Consequently, there are more chances to identify and manage infectious enteritis.

Global Infectious Enteritis Treatment Market Restraints

Adverse Effects Associated with Infectious Enteritis Treatment

Infectious enteritis leads to diarrhea and the subsequent loss of fluid and electrolytes. Maldigestion and malabsorption are the primary physiological processes involved. Therefore, intravenous treatment is initially more successful than oral medication in correcting electrolyte imbalances and fluid loss. Both crystalloids and colloids should be included in the fluid therapy regimen. 

However, the administration of these fluids or any other medications such as penicillin, cephalosporin, antifolate or sulfa combinations, nitroimidazole, glycopeptide, and monobactam antibiotics for the treatment of infectious enteritis may result in additional side effects due to the patient'spatients' known allergies.

Aside from antibiotics, healthcare providers may also give antidiarrheal drugs to relieve symptoms of diarrhea related to enteritis. Nevertheless, these medications may induce adverse effects such as constipation, bloating, and abdominal discomfort. Furthermore, the utilization of these substances can obscure hidden infections, resulting in a delay in receiving suitable medical care and potentially exacerbating the situation. These issues are anticipated to have a detrimental effect on the market's growth throughout the projected timeframe.

Global Infectious Enteritis Treatment Market Opportunity

Ongoing Pharmaceutical Research and Development 

Improvements in healthcare infrastructure drive the market's rise, the use of new diagnostic technologies, continued activities in pharmaceutical research and development, and increasing worries about antibiotic resistance. These characteristics contribute to a favorable business environment for pharmaceutical manufacturers and healthcare providers to mark the issues of infectious enteritis, offering potential opportunities for growth in this industry.

In March 2021, Knight Therapeutics Inc. launched IBSRELA (tenapanor) as an innovative medication for irritable bowel syndrome with constipation (IBS-C) in adult patients. Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a worldwide healthcare firm specializing in gastrointestinal (GI) issues, shared fresh information from four scientific abstracts at the American College of Gastroenterology (ACG) 2023 Annual Scientific Meeting and Postgraduate Course. This research offers more understanding of the effects of linaclotide on symptoms of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC), as well as the impact of these conditions on patients.

Regional Analysis

The global infectious enteritis treatment market analysis is conducted across North America, Europe, Asia-Pacific, the Middle East and Africa, and Latin America.

North America Dominates the Global Market

North America is the most significant global infectious enteritis treatment market shareholder and is estimated to grow at a CAGR of 4.8% over the forecast period.  The key driving factors are the rising incidence of microorganisms causing infectious enteritis and increased investment in healthcare. According to the CDC's December 2022 update, it is predicted that Salmonella bacteria is responsible for approximately 1.35 million infections and 26,500 hospitalizations in the United States annually. Hence, the rising prevalence of salmonella bacteria among individuals is anticipated to propel the demand for efficient treatment, thereby stimulating the expansion of the target market over the specified time.

Moreover, the United States dominates the North American market due to factors such as the significant presence of numerous pharmaceutical companies that produce drugs for infectious enteritis. Furthermore, numerous market participants are actively involved in introducing new products, thereby making a significant contribution to the expansion of the region. In March 2021, Knight Therapeutics Inc. introduced IBSRELA (tenapanor), a groundbreaking medication for irritable bowel syndrome with constipation (IBS-C) in adults. This development is anticipated to stimulate regional growth during the projected timeframe. Consequently, all the variables listed above are expected to contribute significantly to the robust growth of this region during the projected time. 

Europe is anticipated to exhibit a CAGR of 5% over the forecast period. Medical technology and healthcare infrastructure advances in Europe are crucial for enhancing the diagnosis and treatment options for infectious enteritis. The advancement of novel diagnostic tools and therapeutic strategies improves patient outcomes and adds to the growth of the market. Furthermore, the rising occurrences of infectious enteritis, influenced by variables such as shifting dietary patterns, the global expansion of food supply networks, and the emergence of new disease-causing agents, contribute to the need for effective treatment choices.

Additionally, the increasing number of patients presents pharmaceutical businesses and healthcare professionals with prospects to design and promote innovative treatments. In addition, government programs and regulatory frameworks that aim to prevent infectious diseases and promote public health also play a role in driving market growth. Investing in research and development, along with efforts to enhance healthcare accessibility and affordability, promotes innovation and market growth.

The Asia-Pacific region is expected to grow at a significant CAGR in the projected period due to the rising prevalence of infectious enteritis, increasing healthcare awareness, improved healthcare infrastructure, and expanding availability of innovative treatment options. In December 2023, GlaxoSmithKline plc and BioKangtai formed a cooperation to conduct research and promote the use of rotavirus vaccines in mainland China.

Segmental Analysis

The global infectious enteritis treatment market is segmented based on route of administration, drug type, and end-user.

Based on the route of administration, the market is segmented into oral and injectables. 

The oral segment dominated in 2023 because of its convenient administration, excellent patient adherence, and systemic efficacy. Timely treatment is necessary to alleviate symptoms and prevent complications of infectious enteritis. Oral drugs offer an easy and effective method to achieve this.

The injectables segment is expected to exhibit lucrative growth over the forecast period due to their excellent efficacy in treating severe infectious enteritis or in situations where oral delivery is not possible, such as in cases of vomiting or severe dehydration.

Based on drug type, the market is segmented into antibiotics, antivirals, and others.

The antibiotics segment dominated the market in 2023 because of its essential function in fighting the primary bacterial infections that cause numerous instances of infectious enteritis. Enteric diseases, such as Salmonella, Shigella, and Campylobacter, are commonly bacterial, and medicines efficiently target and eradicate these pathogens. However, antivirals are projected to significantly increase in the foreseeable future due to their ability to selectively target and impede viral reproduction, lowering the intensity and duration of symptoms.

The market is segmented by end-users into hospital pharmacies, online pharmacies, home care settings, and other areas. 

The hospital pharmacy segment dominated in 2023 due to the concentrated nature of severe cases that necessitate inpatient care, specialist medical experts' presence, and extensive facilities for testing and treatment within hospital settings. In December 2022, the CDC revised its estimations and said that the Salmonella bacteria causes approximately 1.35 million infections and 26,500 hospitalizations in the US annually. 

The home care setting is the fastest-growing segment due to the rising focus on patient-centered care, developments in home-based medical devices, and the growing demand for recovery in a familiar environment.

Recent Developments

• January 2024 – Cipla (EU) Limited, a subsidiary of Cipla Limited, announced a strategic collaboration with Kemwell Biopharma Private Limited and Manipal Education & Medical Group to establish a joint venture in the United States. Kemwell Biopharma UK Limited and MNI Ventures, Mauritius, are the subsidiaries involved in this collaboration. The primary aim of this collaborative partnership is to create and market innovative Cell therapy products to address significant medical needs that are currently unmet in the United States, Japan, and the European Union.
• December 2023 – Jiangsu Bioperfectus Technologies Co., Ltd. (referred to as "BioPerfectus") announced the release of 10 new Real-Time PCR Kits developed independently by BioPerfectus. 
• February 2024 – AbbVie (NYSE: ABBV) has disclosed that 17 studies sponsored by AbbVie have been accepted for presentation at the 19th Congress of the European Crohn's and Colitis Organisation (ECCO). These submissions include fresh data from AbbVie's portfolio focused on inflammatory bowel disease (IBD). 
• February 2024 – Viatris Inc. (NASDAQ: VTRS) and Idorsia Ltd (SIX: IDIA) have recently partnered for a substantial global research and development collaboration. As part of this collaboration, Viatris will gain exclusive global rights to develop and market two Phase 3 assets, possibly acquiring more innovative assets in the future.